Stay updated on SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe page now shows a new revision indicator (v3.6.4) replacing the previous v3.6.3, indicating a minor site/template update rather than a change to trial content.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now shows Revision: v3.6.3, updating the version label from v3.6.2. This represents a minor system update and does not change the study content or results.SummaryDifference0.1%

- Check40 days agoChange DetectedThe page now shows Revision: v3.6.2, replacing v3.6.0, indicating a minor update to the page version. This update does not alter the study information or how users interact with the page.SummaryDifference0.1%

- Check55 days agoChange DetectedNew help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study). A recruitment status note, 'No longer looking for participants', indicates recruitment closure, and there is a minor heading format change to Intervention/Treatment along with a revision tag updated to v3.6.0.SummaryDifference0.5%

- Check62 days agoChange DetectedThe page revision tag was updated from v3.5.4 to v3.5.5, indicating a minor maintenance update to the page without altering the study details.SummaryDifference0.1%

- Check76 days agoChange DetectedThe page now displays an updated site revision label 'Revision: v3.5.4'. This reflects a new version of the page template and does not alter study data or eligibility criteria.SummaryDifference0.1%

Stay in the know with updates to SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SB3 vs. Herceptin® in HER2+ Breast Cancer Clinical Trial page.